Breaking News

Bio-Techne Invests in New GMP Manufacturing Facility

Will supply raw materials for cell therapy production.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bio-Techne Corporation has unveiled plans to invest between $40-50 million to expand its GMP-grade protein production capacity. This investment will fund a new facility that is specifically dedicated to supporting the large-scale production of GMP-grade materials, including E. coli-derived recombinant proteins, which are an essential component for many bioprocessing and cell therapy manufacturing workflows.   According to the company, the current global GMP-grade raw material supply for cell the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters